MedTrace Logo

Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment

NCT07591779 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-05-22

No results posted yet for this study

Summary

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.

This research will:

In the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel "Nano-Cur" treatment currently under development.

Conditions

  • Charcot-Marie-Tooth Disease, Type IA
  • Peripheral Neuropathy Hereditary
  • Motor Activity
  • Walking, Difficulty
  • Neuromuscular Diseases

Sponsors & Collaborators

  • Limoges University

    collaborator OTHER

  • University Hospital, Limoges

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-04-15
Completion
2027-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07591779 on ClinicalTrials.gov